Core #2 Preclinical testing Milton V. Marshall, Ph.D. DABT The preclinical core will provide services to the NTR program to develop safety and toxicity profiles of candidate imaging agents. Facilities are available in our satellite facility at BCM to house rodents for safety and toxicity testing of molecular imaging agents. Should larger animals be needed, additional space is available through the BCM Center for Comparative Medicine (CCM). CCM personnel who work on GLP studies have received training in Good Laboratory Practices, and some personnel have previous work experience in a GLP facility. Thus, facilities and personnel are available to conduct GLP-compliant preclinical safety and toxicity studies as needed under this program. Dr. Marshall has experience in drug development using different animal models, including rodents, dogs, and primates;his work in preclinical medical device development includes use of farm animals (sheep, pigs, and calves). Brian Gibson, DVM, will work with Dr. Marshall in study design and in monitoring the health of animals on safety studies. Because BCM does not maintain a GLP-compliant clinical chemistry and hematology laboratory, samples will be sent to a local GLPcompliant facility, Equine Laboratories. Likewise, histopathology will be conducted at a GLP-compliant facility, and slides will be reviewed by a board-certified Veterinary Pathologist with experience in preclinical drug and device development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA136404-05
Application #
8381300
Study Section
Special Emphasis Panel (ZCA1-SRRB-9)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$103,717
Indirect Cost
$33,575
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Rasmussen, John C; Aldrich, Melissa B; Tan, I-Chih et al. (2016) Lymphatic transport in patients with chronic venous insufficiency and venous leg ulcers following sequential pneumatic compression. J Vasc Surg Venous Lymphat Disord 4:9-17
Gonzalez-Garay, M L; Aldrich, M B; Rasmussen, J C et al. (2016) A novel mutation in CELSR1 is associated with hereditary lymphedema. Vasc Cell 8:1
Zhu, Banghe; Rasmussen, John C; Litorja, Maritoni et al. (2016) Determining the Performance of Fluorescence Molecular Imaging Devices Using Traceable Working Standards With SI Units of Radiance. IEEE Trans Med Imaging 35:802-11
Wang, Xuejuan; Aldrich, Melissa B; Yang, Zhi et al. (2016) Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents. Chin J Cancer Res 28:362-9
Zhu, B; Sevick-Muraca, E M (2015) A review of performance of near-infrared fluorescence imaging devices used in clinical studies. Br J Radiol 88:20140547
Gao, Peng; Pinkston, Kenneth L; Wilganowski, Nathaniel et al. (2015) Deglycosylation of mAb by EndoS for improved molecular imaging. Mol Imaging Biol 17:195-203
Rasmussen, John C; Fife, Caroline E; Sevick-Muraca, Eva M (2015) Near-Infrared Fluorescence Lymphatic Imaging in Lymphangiomatosis. Lymphat Res Biol 13:195-201
Ghosh, Sukhen C; Pinkston, Kenneth L; Robinson, Holly et al. (2015) Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates. Nucl Med Biol 42:177-83
Agollah, Germaine D; Gonzalez-Garay, Manuel L; Rasmussen, John C et al. (2014) Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction. PLoS One 9:e112548
Rasmussen, John C; Herbst, Karen L; Aldrich, Melissa B et al. (2014) An abnormal lymphatic phenotype is associated with subcutaneous adipose tissue deposits in Dercum's disease. Obesity (Silver Spring) 22:2186-92

Showing the most recent 10 out of 33 publications